{"id":36980,"date":"2025-07-09T11:42:41","date_gmt":"2025-07-09T03:42:41","guid":{"rendered":"https:\/\/flcube.com\/?p=36980"},"modified":"2025-07-09T11:42:42","modified_gmt":"2025-07-09T03:42:42","slug":"boston-scientifics-farapulse-gains-fda-approval-for-expanded-use-in-persistent-atrial-fibrillation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36980","title":{"rendered":"Boston Scientific’s FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation"},"content":{"rendered":"\n

US-based Boston Scientific Corporation (NYSE: BSX<\/a>) announced that it has received US FDA approval for label expansion relating to its FARAPULSE pulsed field ablation (PFA) system. The product can now be used to treat drug-refractory, symptomatic persistent atrial fibrillation (AF), a condition where the heart beats abnormally for at least seven days.<\/p>\n\n\n\n

Mechanism and Approval<\/strong>
The FARAPULSE PFA system delivers pulsed electric field energy via a catheter to ablate heart tissue, thereby treating atrial fibrillation. This expanded approval is primarily supported by clinical evidence from the first phase of the ADVANTAGE AF trial, which met its primary safety and efficacy endpoints.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
Results from the trial showed that no stroke, pulmonary vein stenosis, atrial-esophageal fistula, or major access complications occurred. The symptomatic AF recurrence-free rate was 85.3%. For operators who have performed three or more procedures, the freedom from persistent AF symptoms after FARAPULSE treatment increased to 91.4%.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for…<\/p>\n","protected":false},"author":1,"featured_media":36983,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[315,1160,15],"class_list":["post-36980","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-boston-scientific","tag-nyse-bsx","tag-product-approvals"],"yoast_head":"\nBoston Scientific's FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for label expansion relating to its FARAPULSE pulsed field ablation (PFA) system. The product can now be used to treat drug-refractory, symptomatic persistent atrial fibrillation (AF), a condition where the heart beats abnormally for at least seven days.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36980\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boston Scientific's FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation\" \/>\n<meta property=\"og:description\" content=\"US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for label expansion relating to its FARAPULSE pulsed field ablation (PFA) system. The product can now be used to treat drug-refractory, symptomatic persistent atrial fibrillation (AF), a condition where the heart beats abnormally for at least seven days.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36980\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-09T03:42:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-09T03:42:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36980#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36980\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boston Scientific’s FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation\",\"datePublished\":\"2025-07-09T03:42:41+00:00\",\"dateModified\":\"2025-07-09T03:42:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36980\"},\"wordCount\":166,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36980#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0901.webp\",\"keywords\":[\"Boston Scientific\",\"NYSE: BSX\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36980#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36980\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36980\",\"name\":\"Boston Scientific's FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36980#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36980#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0901.webp\",\"datePublished\":\"2025-07-09T03:42:41+00:00\",\"dateModified\":\"2025-07-09T03:42:42+00:00\",\"description\":\"US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for label expansion relating to its FARAPULSE pulsed field ablation (PFA) system. The product can now be used to treat drug-refractory, symptomatic persistent atrial fibrillation (AF), a condition where the heart beats abnormally for at least seven days.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36980#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36980\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36980#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Boston Scientific's FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36980#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boston Scientific’s FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boston Scientific's FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation - Insight, China's Pharmaceutical Industry","description":"US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for label expansion relating to its FARAPULSE pulsed field ablation (PFA) system. The product can now be used to treat drug-refractory, symptomatic persistent atrial fibrillation (AF), a condition where the heart beats abnormally for at least seven days.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36980","og_locale":"en_US","og_type":"article","og_title":"Boston Scientific's FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation","og_description":"US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for label expansion relating to its FARAPULSE pulsed field ablation (PFA) system. The product can now be used to treat drug-refractory, symptomatic persistent atrial fibrillation (AF), a condition where the heart beats abnormally for at least seven days.","og_url":"https:\/\/flcube.com\/?p=36980","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-09T03:42:41+00:00","article_modified_time":"2025-07-09T03:42:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36980#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36980"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boston Scientific’s FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation","datePublished":"2025-07-09T03:42:41+00:00","dateModified":"2025-07-09T03:42:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36980"},"wordCount":166,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36980#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0901.webp","keywords":["Boston Scientific","NYSE: BSX","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36980#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36980","url":"https:\/\/flcube.com\/?p=36980","name":"Boston Scientific's FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36980#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36980#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0901.webp","datePublished":"2025-07-09T03:42:41+00:00","dateModified":"2025-07-09T03:42:42+00:00","description":"US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for label expansion relating to its FARAPULSE pulsed field ablation (PFA) system. The product can now be used to treat drug-refractory, symptomatic persistent atrial fibrillation (AF), a condition where the heart beats abnormally for at least seven days.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36980#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36980"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36980#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0901.webp","width":1080,"height":608,"caption":"Boston Scientific's FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36980#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boston Scientific’s FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36980"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36980\/revisions"}],"predecessor-version":[{"id":36984,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36980\/revisions\/36984"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36983"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}